EDIT — Editas Medicine Share News
0.000.00%
Last trade - 00:00- $382.41m
- $226.51m
- $40.52m
Editas Medicine Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Editas Medicine Announces New Safety And Efficacy Data From The Edithal Trial Of Reni-Cel
Brief: Editas Medicine Q1 Net Income USD -61.95 Million
Health Rounds: Editas gene editing treatment restores sight in inherited blindness
Editas Medicine Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Editas Medicine And Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
U.S. RESEARCH ROUNDUP-Okta, Salesforce, Sarepta Therapeutics
Editas Medicine rises on narrower Q4 loss
Editas Medicine Inc expected to post a loss of 54 cents a share - Earnings Preview
Editas Medicine Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Editas Medicine Highlights Strategic Priorities at the J.P. Morgan Healthcare Conference
U.S. RESEARCH ROUNDUP- Goldman Sachs, IBM, JP Morgan
U.S. STOCKS ON THE MOVE-Xpeng, Canopy Growth, ReShape Lifesciences
U.S. STOCKS ON THE MOVE-Southwest Airlines, Canopy Growth, US Steel
Editas up on agreement with Vertex Pharma for gene editing tech
Brief: Editas Medicine And Vertex Pharmaceuticals Enter Into Non-Exclusive License Agreement For Cas9
U.S. RESEARCH ROUNDUP-Adobe, Oracle, Visa
Brief: Editas Medicine Announces New Edit-301 Safety And Efficacy Data In 17 Patients
Editas Medicine Inc reports results for the quarter ended in September - Earnings Summary